The DOI matches its Crossref record.
Double‐Blind, Placebo‐Controlled Trial of Topiramate as Add‐on Therapy in Patients with Refractory Partial Seizures
Abstract
Summary: In a double‐blind, randomized, parallel‐group trial, we compared topiramate (TPM) with placebo as addon therapy in patients with refractory partial epilepsy. TPM was titrated either to the target dosage of 800 mg/ day [400 mg twice daily (b. i. d.)] or to the maximal tolerated dose if lower. Twenty‐eight (28) patients were randomized to each treatment group. In the intent‐to‐treat analysis, the net median percent reduction relative to placebo in average monthly seizure rate was 54% for patients in the TPM group (p < 0.001). None of the placebo‐treated patients and 43% of the patients treated with TPM experienced 250% reduction in seizures (p = 0.001), and 36% of patients assigned to TPM had a 75–100% reduction in seizures (p < 0.01). Secondarily generalized seizures were also significantly reduced in the TPM group (p = 0.044). The most common adverse events (AE) reported in the TPM group were fatigue, impaired concentation, weight loss, dizziness, and paresthesias. AE occurring either during the rapid titration of TPM or at high dosages led 21% of TPM‐treated patients to withdraw from the study. Half of these occurred during the titration study period. No serious AE or clinically important changes in clinical laboratory measures were observed. The present study further establishes the favorable profile and good benefithisk ratio of TPM in resistant partial epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Seizure Reduction and Quality of Life Improvements in People with Epilepsy
Birbeck, G. L., Hays, R. D., Cui, X., & Vickrey, B. G. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.32201.x · Cited by 395
White, H. S., Brown, S. D., Woodhead, J. H., Skeen, G. A., & Wolf, H. H. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(97)00045-4 · Cited by 356
Zimmermann, U., Kraus, T., Himmerich, H., Schuld, A., & Pollmächer, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00018-9 · Cited by 347
The New Antiepileptic Drugs: Scientific Review
LaRoche, S. M., & Helmers, S. L. (2004) · JAMA · doi:10.1001/jama.291.5.605 · Cited by 279
Metadata
- Authors
- Ben‐Menachem, E., Henriksen, O., Dam, M., Mikkelsen, M., Schmidt, D., Reid, S., Reife, R., Kramer, L., Pledger, G., & Karim, R.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 1996-06
- Volume
- 37
- Issue
- 6
- Pages
- 539-543
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2117449343
- Cited by
- 243
- References
- 0
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double‐Blind, Placebo‐Controlled Trial of Topiramate as Add‐on Therapy in Patients with Refractory Partial Seizures. https://app.cochat.ai/papers/10.1111/j.1528-1157.1996.tb00606.x
- The paper
- Ben‐Menachem, E., Henriksen, O., Dam, M., Mikkelsen, M., Schmidt, D., Reid, S., Reife, R., Kramer, L., Pledger, G., & Karim, R. (1996). Double‐Blind, Placebo‐Controlled Trial of Topiramate as Add‐on Therapy in Patients with Refractory Partial Seizures. Epilepsia. https://doi.org/10.1111/j.1528-1157.1996.tb00606.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.